Conditions: Persistent or Permanent Nonvalvular Atrial Fibrillation
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 523
Healthy volunteers: no

Brief summary:
The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and systemic embolic events (moderate to high risk patients).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: AZD0837 intervention 2: VKA INR 2-3
Intervention descriptions: intervention 1: Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od intervention 2: Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5

Protocol document: